Announcements Trials
Browse Landscape

Phase

Phase 3 32Phase 2 28Phase 1/2 9Phase 1 8Phase 4 5Phase NA 2Phase EARLY_PHASE1 2Phase 2/3 1

Status

Completed 3Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 4Leiomyoma 1

Interventions

Letrozole 5Tamoxifen 4Anastrozole 4ribociclib 3exemestane 3atezolizumab 3Vancomycin 3Nivolumab 3Magnetic Resonance Spectroscopy 3Injections 3Human Papillomavirus Recombinant Vaccine nonavalent 3Dexamethasone 3Carboplatin 3trametinib 2relatlimab 2pembrolizumab 2encorafenib 2dabrafenib 2binimetinib 2asciminib 2Specimen Handling 2Rituximab 2Prednisone 2Papillomavirus Vaccines 2Oxaliplatin 2Medroxyprogesterone Acetate 2Leucovorin 2Lenalidomide 2Ipilimumab 2Immune Checkpoint Inhibitors 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 4 × Letrozole × 90 days × Clear all
NCT06143631 2026-05-20

PLUM

University of California, San Francisco

Phase 4 Recruiting
140 enrolled

Leiomyoma

NCT01127295 2026-04-14

PHACS

Institut Claudius Regaud

Phase 4 Completed
2,000 enrolled
Breast

Breast Neoplasms

NCT01553903 2026-04-14

OXYTAM

Institut Claudius Regaud

Phase 4 Completed
29 enrolled
Breast

Breast Neoplasms

NCT01612871 2026-04-14

MIRHO

Institut Claudius Regaud

Phase 4 Completed
39 enrolled
Breast

Breast Neoplasms

NCT05161195 2026-04-02

Roll-over Study to Allow Continued Access to Ribociclib

Novartis

Phase 4 Active not recruiting
134 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡